---
title: "Crescent Biopharma, Inc. (CBIO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CBIO.US.md"
symbol: "CBIO.US"
name: "Crescent Biopharma, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T10:05:36.086Z"
locales:
  - [en](https://longbridge.com/en/quote/CBIO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CBIO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CBIO.US.md)
---

# Crescent Biopharma, Inc. (CBIO.US)

## Company Overview

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [crescentbiopharma.com](https://crescentbiopharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.56)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 119 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -449.67% |  |
| P/B Ratio | 2.83 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 509249054.16 |  |
| Revenue | 11883000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | -1363.94% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | -449.67% | E |
| Total Assets YoY | 677.70% | A |
| Net Assets YoY | 802.75% | A |
| Cash Flow Margin | 42.95% | C |
| OCF YoY | 0.00% | D |
| Turnover | 0.00 | E |
| Gearing Ratio | 7.67% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Crescent Biopharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-449.67%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.83",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "509249054.16",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "11883000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-1363.94%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-449.67%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "677.70%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "802.75%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "42.95%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "7.67%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.14 | 308/386 | - | - | - |
| PB | 2.83 | 251/386 | 2.64 | 2.02 | 1.58 |
| PS (TTM) | 42.86 | 229/386 | 49.60 | 43.02 | 29.38 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-04T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 89% |
| Overweight | 1 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 23.90 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CBIO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CBIO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CBIO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CBIO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**